Skip to main content
Journal cover image

Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.

Publication ,  Journal Article
Perfect, JR; Dodds Ashley, E; Drew, R
Published in: Clin Infect Dis
October 15, 2004

BACKGROUND: Emphasis has been placed on the need for antifungal prophylaxis when transplanted organs are directly exposed to the environment. In lung transplantation, one strategy for prevention has been aerosolization of polyenes into the lung. Despite widespread use of amphotericin B aerosols, there are still few studies on how to validate their effectiveness or optimize pharmacokinetics. METHODS: We compared results of several of our own studies of lung transplant recipients receiving formulations of amphotericin B with results of other studies. RESULTS: Recent aerosol studies suggest that aerosols of a lipid formulation of amphotericin B are safe and better tolerated than is amphotericin B deoxycholate. Their use in prophylaxis is associated with very few pulmonary fungal infections. CONCLUSION: This safe drug delivery at a local body site to directly protect the transplanted organ without systemic antifungal drug exposure is attractive from a cost and toxicity standpoint. However, careful multicenter, comparative studies are still needed to ensure that this strategy is consistently successful.

Duke Scholars

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 15, 2004

Volume

39 Suppl 4

Start / End Page

S207 / S210

Location

United States

Related Subject Headings

  • Transplantation
  • Research Design
  • Preventive Medicine
  • Mycoses
  • Microbiology
  • Lung Transplantation
  • Immunocompromised Host
  • Humans
  • Drug Combinations
  • Deoxycholic Acid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Perfect, J. R., Dodds Ashley, E., & Drew, R. (2004). Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis, 39 Suppl 4, S207–S210. https://doi.org/10.1086/421958
Perfect, John R., Elizabeth Dodds Ashley, and Richard Drew. “Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.Clin Infect Dis 39 Suppl 4 (October 15, 2004): S207–10. https://doi.org/10.1086/421958.
Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004 Oct 15;39 Suppl 4:S207–10.
Perfect, John R., et al. “Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.Clin Infect Dis, vol. 39 Suppl 4, Oct. 2004, pp. S207–10. Pubmed, doi:10.1086/421958.
Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004 Oct 15;39 Suppl 4:S207–S210.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 15, 2004

Volume

39 Suppl 4

Start / End Page

S207 / S210

Location

United States

Related Subject Headings

  • Transplantation
  • Research Design
  • Preventive Medicine
  • Mycoses
  • Microbiology
  • Lung Transplantation
  • Immunocompromised Host
  • Humans
  • Drug Combinations
  • Deoxycholic Acid